SCHEMBL27159792

SCHEMBL27159792

O=c1[nH]cc(F)c2cc(B(O)O)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.42
▸ AKR1C3 P42330 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.35
▸ ENPP2 Q13822 1/20 0.35
▸ ROCK1 Q13464 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ TDO2 P48775 1/20 0.33
▸ ERCC1 P07992 2/20 0.33
▸ ERCC4 Q92889 2/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ CYP19A1 P11511 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ THPO P40225 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ HBB P68871 1/20 0.32
▸ PMP22 Q01453 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30816158 1.00 AR (0.42) ARAKR1C3KDM4EENPP2ROCK1
SCHEMBL29914860 0.80 ROCK1 (0.41) ARAKR1C3KDM4EENPP2ROCK1
SCHEMBL27159981 0.80 ROCK1 (0.41) ARAKR1C3KDM4EENPP2ROCK1
SCHEMBL27159699 0.77 ALDH1A1 (0.32) ARAKR1C3ALDH1A1LMNAMAPT
SCHEMBL27159718 0.75 AR (0.34) ARAKR1C3ERCC1ERCC4ALDH1A1
SCHEMBL15010561 0.74 CHEK1 (0.46) ARAKR1C3ROCK1ERCC1ERCC4
SCHEMBL31351769 0.74 PARP1 (0.46) ARAKR1C3KDM4EPARP1ALDH1A1
SCHEMBL20896393 0.71 ALDH1A1 (0.34) ARAKR1C3ERCC1ERCC4ALDH1A1
SCHEMBL18954023 0.70 PARP1 (0.55) ARAKR1C3KDM4EROCK1PARP1
SCHEMBL29914939 0.69 PARP1 (0.49) ARAKR1C3KDM4EERCC1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425479-A1 HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-12-26 — — US disclosed
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 — — US disclosed
EP-4330246-A1 HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) Ontario Institute for Cancer Research (OICR) (CA) 2024-03-06 — — EP disclosed
CN-117597336-A Halogen substituted amino aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) 安大略省癌症研究所(OICR) 2024-02-23 — — CN disclosed
WO-2022226665-A1 HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 — — WO disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 AR 4179/4885AKR1C3 2993/4885KDM4E 1986/4885
US-20240425479-A1 HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) DCK, CMPK1, WNK1 AR 3844/4885AKR1C3 2923/4885KDM4E 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback